



## **BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025**

February 24, 2025

**MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE)** -- [BioNTech SE](#) (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the fourth quarter and full year 2024 on Monday, March 10, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

To access the live conference call via telephone, please register via this [link](#). Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this [link](#).

Participants may also access the slides and the webcast of the conference call via the "Events & Presentations" page in the Investor Relations section of the Company's website at [www.BioNTech.com](http://www.BioNTech.com). A replay of the webcast will be made available shortly after the call and archived on the Company's website for 30 days following the call.

### **About BioNTech**

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms with the intent of rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.

For more information, please visit [www.BioNTech.com](http://www.BioNTech.com).

### **CONTACTS**

#### **Investor Relations**

Michael Horowicz

[Investors@biontech.de](mailto:Investors@biontech.de)

#### **Media Relations**

Jasmina Alatovic

[Media@biontech.de](mailto:Media@biontech.de)